On the one hand, pharmaceutical inhibition and fibroblast-specific deletion of Twist1 have been shown to mitigate liver fibrosis (Dong et al., 2020) and skin fibrosis (Palumbo-Zerr et al., 2017), respectively, supporting Twist1 as a promoter of tissue fibrosis. This evidence concerns the gene TWIST1 and Hepatic fibrosis.